Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
Company profile
Ticker
AXDX
Exchange
Website
CEO
John Phillips
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Revvity • Bio-Rad Laboratories • Waters • Illumina • Avantor • Mettler-Toledo International • Bruker • Seer • Prenetics Global Limited ...
Former names
ACCELR8 TECHNOLOGY CORP
SEC CIK
Corporate docs
Subsidiaries
Accelerate Diagnostics UK Limited • Accelerate Diagnostics S.L. • Accelerate Diagnostics GmbH • Accelerate Diagnostics SARL • Accelerate Diagnostics Pty Ltd • Accelerate Diagnostics B.V. • Accelerate Diagnostics Holdings, LLC ...
IRS number
841072256
AXDX stock data
Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
24 May 23
8-K
Other Events
24 May 23
8-K
Other Events
22 May 23
DEFA14A
Additional proxy soliciting materials
17 May 23
8-K
Other Events
16 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Other Events
15 May 23
8-K
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
11 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Entry into a Material Definitive Agreement
21 Apr 23
Transcripts
AXDX
Earnings call transcript
2023 Q1
11 May 23
AXDX
Earnings call transcript
2022 Q4
29 Mar 23
AXDX
Earnings call transcript
2022 Q3
15 Nov 22
AXDX
Earnings call transcript
2022 Q2
16 Aug 22
AXDX
Earnings call transcript
2022 Q1
17 May 22
AXDX
Earnings call transcript
2021 Q4
9 Mar 22
AXDX
Earnings call transcript
2021 Q3
10 Nov 21
AXDX
Earnings call transcript
2021 Q2
8 Aug 21
AXDX
Earnings call transcript
2021 Q1
7 May 21
AXDX
Earnings call transcript
2020 Q4
24 Feb 21
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 29.41 mm | 29.41 mm | 29.41 mm | 29.41 mm | 29.41 mm | 29.41 mm |
| Cash burn (monthly) | 1.83 mm | (no burn) | 5.60 mm | 5.49 mm | 4.46 mm | 4.12 mm |
| Cash used (since last report) | 3.61 mm | n/a | 11.03 mm | 10.82 mm | 8.78 mm | 8.12 mm |
| Cash remaining | 25.80 mm | n/a | 18.38 mm | 18.59 mm | 20.63 mm | 21.29 mm |
| Runway (months of cash) | 14.1 | n/a | 3.3 | 3.4 | 4.6 | 5.2 |
Institutional ownership, Q2 2022
34.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 75 |
| Opened positions | 10 |
| Closed positions | 42 |
| Increased positions | 12 |
| Reduced positions | 24 |
| 13F shares | Current |
|---|---|
| Total value | 111.57 mm |
| Total shares | 34.66 mm |
| Total puts | 834.20 k |
| Total calls | 29.90 k |
| Total put/call ratio | 27.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Schuler Jack W | 18.28 mm | $90.69 mm |
| Griffin Asset Management | 3.98 mm | $3.95 mm |
| Oracle Investment Management | 2.45 mm | $2.43 mm |
| Vanguard | 2.30 mm | $2.29 mm |
| Citadel Advisors | 1.19 mm | $1.18 mm |
| Cannell Peter B & Co | 1.09 mm | $1.08 mm |
| Cladis Investment Advisory | 583.50 k | $579.00 k |
| BLK Blackrock | 566.48 k | $562.00 k |
| JPM JPMorgan Chase & Co. | 379.34 k | $377.00 k |
| Belpointe Asset Management | 347.85 k | $345.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 May 23 | Larry Michael Mertz | Common Stock | Sell | Dispose S | No | No | 0.72 | 769 | 553.68 | 525,695 |
| 22 May 23 | Larry Michael Mertz | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,836 | 0.00 | 526,464 |
| 22 May 23 | Larry Michael Mertz | Common Stock | Sell | Dispose S | No | No | 0.72 | 2,711 | 1.95 k | 523,628 |
| 22 May 23 | Larry Michael Mertz | Common Stock | Option exercise | Acquire M | No | No | 0 | 10,000 | 0.00 | 526,339 |
| 22 May 23 | Larry Michael Mertz | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,836 | 0.00 | 2,835 |
| 22 May 23 | Larry Michael Mertz | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,000 | 0.00 | 10,000 |
| 19 May 23 | Watts Charles M | Common Stock | Option exercise | Acquire M | No | No | 0 | 69,619 | 0.00 | 69,619 |
| 19 May 23 | Watts Charles M | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 69,619 | 0.00 | 0 |
| 19 May 23 | Brown Thomas D | Common Stock | Option exercise | Acquire M | No | No | 0 | 69,619 | 0.00 | 116,160 |
| 19 May 23 | Brown Thomas D | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 69,619 | 0.00 | 0 |
News
Recap: Accelerate Diagnostics Q1 Earnings
11 May 23
Accelerate Diagnostics Q1 EPS $(0.17) Misses $(0.14) Estimate, Sales $2.81M Miss $3.35M Estimate
11 May 23
Earnings Scheduled For May 11, 2023
11 May 23
Why Guardforce AI Shares Are Trading Lower By 59%; Here Are 20 Stocks Moving Premarket
3 May 23
Top 5 Health Care Stocks That May Collapse
31 Mar 23
Press releases
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
11 May 23
Accelerate Diagnostics scheduled call to review 2023 first quarter results
27 Apr 23
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 23
Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results
15 Mar 23
Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement
14 Mar 23